Potential implication of residual viremia in patients on effective antiretroviral therapy

AIDS Research and Human Retroviruses

Volumn 31, Issue 1, 2015, Pages 25-35

  Sahu, Gautam K ^a  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS DNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; DNA INTEGRATION; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LATENT VIRUS INFECTION; LIMIT OF DETECTION; MEMORY T LYMPHOCYTE; MOLECULAR PHYLOGENY; NONSENSE MUTATION; PRIORITY JOURNAL; REMISSION; RESIDUAL VIREMIA; REVIEW; T LYMPHOCYTE SUBPOPULATION; VIRAL CLEARANCE; VIREMIA; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; VIROLOGY; VIRUS LATENCY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; VIRAL LOAD; VIREMIA; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84922971305     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2014.0194     Document Type: Review

References (139)

1. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team [see comment]. N Engl J Med 1997;337(11):725-733
2. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy [see comment]. N Engl J Med 1997;337(11):734-739
3. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373(6510):117-122
4. Perelson AS, Neumann AU, Markowitz M, et al.: HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271(5255):1582-1586
5. Markowitz M, Louie M, Hurley A, et al.: A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and Tcell decay in vivo. J Virol 2003;77(8):5037-5038
6. Ho DD, Neumann AU, Perelson AS, et al.: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373(6510):123-126
7. Perelson AS, Essunger P, Cao Y, et al.: Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997;387(6629):188-191
8. Andrade A, Rosenkranz SL, Cillo AR, et al.: Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. J Infect Dis 2013;208(6):884-891
9. Palmer S, Maldarelli F, Wiegand A, et al.: Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2008;105(10):3879-3884
10. Hermankova M, Ray SC, Ruff C, et al.: HIV-1 drug resistance profiles in children and adults with viral load of 50 copies/ml receiving combination therapy JAMA 2001 286 (2) 196-207
11. Maldarelli F, Palmer S, King MS, et al.: ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 2007;3(4):e46
12. Dornadula G, Zhang H, VanUitert B, et al.: Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy [see comment]. JAMA 1999;282(17):1627-1632
13. Gunthard HF, Havlir DV, Fiscus S, et al.: Residual human immunodeficiency virus (HIV) type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. J Infect Dis 2001;183(9):1318-1327
14. Havlir DV, Strain MC, Clerici M, et al.: Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003;77(20):11212-11219
15. Nettles RE, Kieffer TL, Simmons RP, et al.: Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin Infect Dis 2004;39(7):1030-1037
16. Palmer S, Wiegand AP, Maldarelli F, et al.: New realtime reverse transcriptase-initiated PCR assay with singlecopy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003;41(10):4531-4536
17. Fletcher CV, Staskus K, Wietgrefe SW, et al.: Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci USA 2014;111(6):2307-2312
18. Hatano H, Strain MC, Scherzer R, et al.: Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: A randomized, placebo-controlled trial. J Infect Dis 2013;208(9):1436-1442
19. Buzon MJ, Massanella M, Llibre JM, et al.: HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010;16(4):460-465
20. Sigal A, Kim JT, Balazs AB, et al.: Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2012;205:S375-S382
21. McMahon D, Jones J, Wiegand A, et al.: Short-course raltegravir intensification does not reduce persistent lowlevel viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 2010;50(6):912-919.
22. Gandhi RT, Zheng L, Bosch RJ, et al.: The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: A randomized controlled trial. PLoS Med 2010;7(8
23. Yukl SA, Shergill AK, McQuaid K, et al.: Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 2010;24(16): 2451-2460
24. Grant PM, Palmer S, Bendavid E, et al.: Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: Effects on level of residual viremia and quality of life. J Clin Virol 2009;46(4):305-308
25. Dinoso JB, Kim SY, Wiegand AM, et al.: Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci USA 2009;106(23):9403-9408
26. Besson GJ, McMahon D, Maldarelli F, and Mellors JW: Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy. Clin Infect Dis 2012;54(3): 451-453
27. Persaud D, Siberry GK, Ahonkhai A, et al.: Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol 2004;78(2):968-979
28. Kieffer TL, Finucane MM, Nettles RE, et al.: Genotypic analysis of HIV-1 drug resistance at the limit of detection: Virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis 2004;189(8):1452-1465
29. Kearney MF, Spindler J, Shao W, et al.: Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. PLoS Pathog 2014;10(3):e1004010
30. Evering TH, Mehandru S, Racz P, et al.: Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS Pathog 2012;8(2):e1002506
31. Josefsson L, von Stockenstrom S, Faria NR, et al.: The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proc Natl Acad Sci USA 2013;110(51):E4987-4996
32. Buzon MJ, Codoner FM, Frost SD, et al.: Deep molecular characterization of HIV-1 dynamics under suppressive HAART. PLoS Pathog 2011;7(10):e1002314
33. Shen L and Siliciano RF: Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol 2008;122(1):22-28
34. Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy [see comment]. Science 1997;278(5341): 1295-1300
35. Chun TW, Stuyver L, Mizell SB, et al.: Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997;94(24): 13193-13197
36. Wong JK, Hezareh M, Gunthard HF, et al.: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia [see comment]. Science 1997;278(5341): 1291-1295
37. Chun TW, Carruth L, Finzi D, et al.: Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997;387(6629):183-188
38. Chun TW, Finzi D, Margolick J, et al.: In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency. Nat Med 1995;1(12):1284-1290
39. Siliciano JD, Kajdas J, Finzi D, et al.: Long-term followup studies confirm the stability of the latent reservoir for HIV-1 in resting CD4 + T cells. Nat Med 2003;9(6): 727-728
40. Pierson T, McArthur J, and Siliciano RF: Reservoirs for HIV-1: Mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol 2000;18:665-708
41. Anderson JA, Archin NM, Ince W, et al.: Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells. J Virol 2011;85(10):5220-5223
42. Sahu GK, Paar D, Frost SD, et al.: Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells. J Med Virol 2009;81(1):9-15
43. Brennan TP, Woods JO, Sedaghat AR, et al.: Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4 + T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol 2009;83(17):8470-8481
44. Bailey JR, Sedaghat AR, Kieffer T, et al.: Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4 +T cells. J Virol 2006;80(13):6441-6457
45. Mavigner M, Delobel P, Cazabat M, et al.: HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One 2009;4(10):e7658
46. Sahu GK, Sarria JC, and Cloyd MW: Recovery of replication-competent residual HIV-1 from plasma of a patient receiving prolonged, suppressive highly active antiretroviral therapy. J Virol 2010;84(16):8348-8352
47. Luznik L, Kraus G, Guatelli J, et al.: Tat-independent replication of human immunodeficiency viruses. J Clin Invest 1995;95(1):328-332
48. Shen H, Cheng T, Preffer FI, et al.: Intrinsic human immunodeficiency virus type 1 resistance of hematopoietic stem cells despite coreceptor expression. J Virol 1999; 73(1):728-737
49. Neal TF, Holland HK, Baum CM, et al.: CD34 + progenitor cells from asymptomatic patients are not a major reservoir for human immunodeficiency virus-1. Blood 1995;86(5):1749-1756
50. Weichold FF, Zella D, Barabitskaja O, et al.: Neither human immunodeficiency virus-1 (HIV-1) nor HIV-2 infects most-primitive human hematopoietic stem cells as assessed in long-term bone marrow cultures. Blood 1998;91(3):907-915
51. Majka M, Rozmyslowicz T, Lee B, et al.: Bone marrow CD34( + ) cells andmegakaryoblasts secrete beta-chemokines that block infection of hematopoietic cells by M-tropic R5 HIV. J Clin Invest 1999;104(12):1739-1749
52. Zhang J, Scadden DT, and Crumpacker CS: Primitive hematopoietic cells resist HIV-1 infection via p21. J Clin Invest 2007;117(2):473-481
53. Carter CC, Onafuwa-Nuga A, McNamara LA, et al.: HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med 2010;16(4): 446-451
54. Carter CC, McNamara LA, Onafuwa-Nuga A, et al.: HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells. Cell Host Microbe 2011;9(3):223-234
55. Redd AD, AvalosA, and EssexM: Infection of hematopoietic progenitor cells by HIV-1 subtype C, and its association with anemia in southern Africa. Blood 2007;110(9):3143-3149
56. Durand CM, Ghiaur G, Siliciano JD, et al.: HIV-1 DNA is detected in bone marrow populations containing CD4 +T cells but is not found in purified CD34 + hematopoietic progenitor cells in most patients on antiretroviral therapy. J Infect Dis 2013;205(6):1014-1018
57. Josefsson L, Eriksson S, Sinclair E, et al.: Hematopoietic precursor cells isolated from patients on long-term suppressive HIV therapy did not contain HIV-1 DNA. J Infect Dis2012;206(1):28-34
58. Dorival C, Brizzi F, Lelievre JD, et al.: HIV-1 Nef protein expression in human CD34 + progenitors impairs the differentiation of an early T/NK cell precursor. Virology 2008;377(1):207-215
59. Verhasselt B, Naessens E, Verhofstede C, et al.: Human immunodeficiency virus nef gene expression affects generation and function of human T cells, but not dendritic cells. Blood 1999;94(8):2809-2818
60. Van Nuffel A, Arien KK, Stove V, et al.: Primate lentiviral Nef proteins deregulate T-cell development by multiple mechanisms. Retrovirology 2013;10:137
61. Gattinoni L, Lugli E, Ji Y, et al.: A human memory T cell subset with stem cell-like properties. Nat Med 2011; 17(10):1290-1297
62. Lugli E, Dominguez MH, Gattinoni L, et al.: Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest 2013;123(2):594-599
63. Buzon MJ, Sun H, Li C, et al.: HIV-1 persistence in CD4 + T cells with stem cell-like properties. Nat Med 2014;20(2):139-142
64. Wong JK, Hezareh M, Gunthard HF, et al.: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278(5341):1291-1295
65. Chomont N, El-Far M, Ancuta P, et al.: HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009;15(8):893-900
66. Maldarelli F, Wu X, Su L, et al.: HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 2014;345(6193):179-183
67. Wagner TA, McLaughlin S, Garg K, et al.: HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 2014; 345(6196):570-573
68. Bull ME, Learn GH, McElhone S, et al.: Monotypic human immunodeficiency virus type 1 genotypes across the uterine cervix and in blood suggest proliferation of cells with provirus. J Virol 2009;83(12):6020-6028
69. Wagner TA, McKernan JL, Tobin NH, et al.: An increasing proportion of monotypic HIV-1 DNA sequences during antiretroviral treatment suggests proliferation of HIV-infected cells. J Virol 2013;87(3):1770-1778
70. Ikeda T, Shibata J, Yoshimura K, et al.: Recurrent HIV-1 integration at the BACH2 locus in resting CD4 + T cell populations during effective highly active antiretroviral therapy. J Infect Dis 2007;195(5):716-725
71. Ho DD, Rota TR, Hirsch MS. Infection of monocyte/ macrophages by human T lymphotropic virus type III. J Clin Invest 1986;77(5):1712-1715
72. Nicholson JK, Cross GD, Callaway CS, and McDougal JS: In vitro infection of human monocytes with human T lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). J Immunol 1986;137(1):323-329
73. Zalar A, Figueroa MI, Ruibal-Ares B, et al.: Macrophage HIV-1 infection in duodenal tissue of patients on long term HAART. Antiviral Res 2010;87(2):269-271
74. Smith PD, Meng G, Shaw GM, and Li L: Infection of gastrointestinal tract macrophages by HIV-1. J Leukoc Biol 1997;62(1):72-77
75. Williams KC, Corey S, Westmoreland SV, et al.: Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: Implications for the neuropathogenesis of AIDS. J Exp Med 2001;193(8):905-915
76. Bagasra O, Lavi E, Bobroski L, et al.: Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: Identification by the combination of in situ polymerase chain reaction and immunohistochemistry. AIDS 1996;10(6):573-585
77. Churchill MJ, Wesselingh SL, Cowley D, et al.: Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol 2009; 66(2):253-258
78. Wiley CA, Schrier RD, Nelson JA, et al.: Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci USA 1986;83(18):7089-7093
79. Conant K, Tornatore C, Atwood W, et al.: In vivo and in vitro infection of the astrocyte by HIV-1. Adv Neuroimmunol 1994;4(3):287-289
80. Nuovo GJ, Gallery F, MacConnell P, and Braun A: In situ detection of polymerase chain reaction-amplified HIV-1 nucleic acids and tumor necrosis factor-alpha RNA in the central nervous system. Am J Pathol 1994;144(4):659-666
81. Eugenin EA, Clements JE, Zink MC, and Berman JW: Human immunodeficiency virus infection of human astrocytes disrupts blood-brain barrier integrity by a gap junctiondependent mechanism. J Neurosci 2011;31(26):9456-9465
82. Anthony IC, Ramage SN, Carnie FW, et al.: Influence of HAART on HIV-related CNS disease and neuroinflammation. J Neuropathol Exp Neurol 2005;64(6):529-536
83. Ladinsky MS, Kieffer C, Olson G, et al.: Electron tomography of HIV-1 infection in gut-associated lymphoid tissue. PLoS Pathog 2014;10(1):e1003899
84. Burnett JC, Miller-Jensen K, Shah PS, et al.: Control of stochastic gene expression by host factors at the HIV promoter. PLoS Pathog 2009;5(1):e1000260
85. Mansky LM and Temin HM: Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995;69(8):5087-5094
86. Haas A, Zimmermann K, and Oxenius A: Antigen-dependent and -independent mechanisms of T and B cell hyperactivation during chronic HIV-1 infection. J Virol 2011;85(23):12102-12113
87. Sandler NG and Douek DC: Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol 2012;10(9):655-666
88. Kuller LH, Tracy R, Belloso W, et al.: Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008;5(10):e203
89. Ledwaba L, Tavel JA, Khabo P, et al.: Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV disease. PLoS One 2012;7(3):e24243
90. Biancotto A, Grivel JC, Iglehart SJ, et al.: Abnormal activation and cytokine spectra in lymph nodes of people chronically infectedwithHIV-1.Blood 2007;109(10):4272-4279
91. Appay V and Sauce D: Immune activation and inflammation in HIV-1 infection: Causes and consequences. J Pathol 2008;214(2):231-241
92. Giorgi JV, Lyles RH, Matud JL, et al.: Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 2002;29(4):346-355
93. Liu Z, Cumberland WG, Hultin LE, et al.: Elevated CD38 antigen expression on CD8 + T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4 + cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16(2):83-92
94. Guadalupe M, Reay E, Sankaran S, et al.: Severe CD4 +T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003;77(21):11708-11717
95. Mehandru S, Poles MA, Tenner-Racz K, et al.: Primary HIV-1 infection is associated with preferential depletion of CD4 + T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004;200(6):761-770
96. Brenchley JM, Schacker TW, Ruff LE, et al.: CD4 +T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004;200(6):749-759
97. Brenchley JM, Price DA, Schacker TW, et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12(12):1365-1371
98. Brenchley JM, Paiardini M, Knox KS, et al.: Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 2008;112(7):2826-2835
99. Epple HJ, Allers K, Troger H, et al.: Acute HIV infection induces mucosal infiltration with CD4 + and CD8 +T cells, epithelial apoptosis, and a mucosal barrier defect. Gastroenterology 2010;139(4):1289-1300
100. Dandekar S, George MD, and Baumler AJ: Th17 cells, HIV and the gut mucosal barrier. Curr Opin HIV AIDS 2010;5(2):173-178
101. Marchetti G, Tincati C, and Silvestri G: Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin Microbiol Rev 2013;26(1):2-18
102. Kristoff J, Haret-Richter G, Ma D, et al.: Early microbial translocation blockade reduces SIV-mediated inflammation and viral replication. J Clin Invest 2014;124(6):2802-2806
103. Baroncelli S, Galluzzo CM, Pirillo MF, et al.: Microbial translocation is associated with residual viral replication in HAART-treated HIV + subjects with 50copies/ml hiv-1 rna J Clin Virol 2009 46 (4) 367-370
104. Jiang W, Lederman MM, Hunt P, et al.: Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009; 199(8):1177-1185
105. Taiwo B, Hunt PW, Gandhi RT, et al.: CD8 + T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy. J Acquir Immune Defic Syndr 2013;63(1):101-104
106. Marziali M, De Santis W, Carello R, et al.: T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART. AIDS 2006;20(16):2033-2041
107. French MA, King MS, Tschampa JM, et al.: Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4 + T cells. J Infect Dis 2009;200(8): 1212-1215
108. Valdez H, Connick E, Smith KY, et al.: Limited immune restoration after 3 years suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002;16(14):1859-1866
109. Hunt PW, Brenchley J, Sinclair E, et al.: Relationship between T cell activation and CD4 + T cell count in HIVseropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008;197(1):126-133
110. Hatano H, Delwart EL, Norris PJ, et al.: Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol 2009;83(1):329-335
111. Hatano H: Immune activation and HIV persistence: Considerations for novel therapeutic interventions. Curr Opin HIV AIDS 2013;8(3):211-216
112. Yonezawa A, Morita R, Takaori-Kondo A, et al.: Natural alpha interferon-producing cells respond to human immunodeficiency virus type 1 with alpha interferon production and maturation into dendritic cells. J Virol 2003;77(6):3777-3784
113. Fonteneau JF, Larsson M, Beignon AS, et al.: Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J Virol 2004; 78(10):5223-5232
114. Herbeuval JP, Nilsson J, Boasso A, et al.: Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients. Proc Natl Acad Sci USA 2006;103(18):7000-7005
115. Conti L, Fantuzzi L, Del Corno M, et al.: Immunomodulatory effects of the HIV-1 gp120 protein on antigen presenting cells: Implications for AIDS pathogenesis. Immunobiology 2004;209(1-2):99-115
116. Krishnan S, Wilson EM, Sheikh V, et al.: Evidence for innate immune system activation in HIV type 1-infected elite controllers. J Infect Dis 2013;209(6):931-939
117. Hatano H, Yukl SA, Ferre AL, et al.: Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog 2013;9(10):e1003691
118. Llibre JM, Buzon MJ, Massanella M, et al.: Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: A randomized 48-week study. Antivir Ther 2012;17(2):355-364
119. Massanella M, Negredo E, Puig J, et al.: Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery. AIDS 2012;26(18):2285-2293
120. Siliciano JD and Siliciano RF: Recent trends in HIV-1 drug resistance. Curr Opin Virol 2013;3(5):487-494
121. Sethi AK, Celentano DD, Gange SJ, et al.: Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003;37(8):1112-1118
122. Mansky LM: HIV mutagenesis and the evolution of antiretroviral drug resistance. Drug Resist Update 2002; 5(6):219-223
123. Meresse M, March L, Kouanfack C, et al.: Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon. HIV Med 2014;15(8):478-487
124. Davey RT Jr, Bhat N, Yoder C, et al.: HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999; 96(26):15109-15114
125. Fischer M, Hafner R, Schneider C, et al.: HIV RNA in plasma rebounds within days during structured treatment interruptions. AIDS 2003;17(2):195-199
126. Harrigan PR, Whaley M, and Montaner JS: Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 1999;13(8):F59-62
127. Ruiz L, Martinez-Picado J, Romeu J, et al.: Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS 2000;14(4): 397-403
128. Chun TW, Davey RT Jr, Engel D, et al.: Re-emergence of HIV after stopping therapy. Nature 1999;401(6756):874-875
129. Chun TW, Davey RT Jr, Ostrowski M, et al.: Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med 2000;6(7):757-761
130. Joos B, Fischer M, Kuster H, et al.: HIV rebounds from latently infected cells, rather than from continuing lowlevel replication. Proc Natl Acad Sci USA 2008;105(43): 16725-16730
131. Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278(5341):1295-1300
132. Hutter G, Nowak D, Mossner M, et al.: Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. N Engl J Med 2009;360(7):692-698
133. Allers K, Hutter G, Hofmann J, et al.: Evidence for the cure of HIV infection by CCR5delta32/delta32 stem cell transplantation. Blood 2011;117(10):2791-2799
134. Henrich TJ, Hu Z, Li JZ, et al.: Long-term reduction in peripheral blood HIV type 1 reservoirs following reducedintensity conditioning allogeneic stem cell transplantation. J Infect Dis 2013;207(11):1694-1702
135. Henrich TJ, Hanhauser E, Marty FM, et al.: Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: Report of 2 cases. Ann Intern Med 2014;161(5):319-327
136. Hill AL, Rosenbloom DI, Fu F, et al.: Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci USA 2014;111(37):13475-13480
137. Persaud D, Gay H, Ziemniak C, et al.: Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013;369(19):1828-1835
138. Archin NM and Margolis DM: Emerging strategies to deplete the HIV reservoir. Curr Opin Infect Dis 2014; 27(1):29-35
139. Siliciano JD and Siliciano RF: The latent reservoir for HIV-1 in resting CD4 + T cells: A barrier to cure. Curr Opin HIV AIDS 2006;1(2):121-128